SPECT imaging of dopamine transporter sites in normal and MPTP-treated rhesus monkeys

被引:0
|
作者
Fischman, AJ
Babich, JW
Elmaleh, DR
Barrow, SA
Meltzer, P
Hanson, RN
Madras, BK
机构
[1] HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA
[2] ORGANIX INC, BOSTON, MA USA
[3] NORTHEASTERN UNIV, DEPT CHEM, BOSTON, MA 02115 USA
[4] NEW ENGLAND REG PRIMATE RES CTR, SOUTHBOROUGH, MA 01772 USA
关键词
Parkinson's disease; dopamine transporters; iodine-123-IACFT; carbon-11-CFT; MPTP;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Parkinson's disease is characterized by degeneration of dopamine (DA) neurons and their terminals. Since these neurons contain dopamine transporters (DAT), radioligands that bind to these sites are promising radiopharmaceuticals for diagnosis and therapeutic monitoring of disease progression. We evaluated [I-123]-2 beta-carbomethoxy-3 beta-(4-fluorophenyl)-N-(1 -iodoprop-1-en-3-yl)nortropane ([I-123]IACFT) for SPECT imaging in an MPTP model of parkinsonism. Methods: Three rhesus monkeys were imaged before and at 1 and 2 mo after treatment with MPTP. The SPECT results were correlated with motor behavior and PET imaging with [C-11]-2 beta-carbomethoxy-3 beta-aryltropane ([C-11] - CFT). Also, biodistribution was measured by planar imaging. Results: In normal animals, striatal accumulation of radioactivity was-rapid and peaked within 30 min. Striatal accumulation of [I-123]IACFT was nearly completely displaceable with unlabeled CFT (1 mg/kg) but was not affected by a similar dose of the serotonin (5-HT) transport inhibitor, citalopram. The striatal to cerebellar ratio measured at 30 min. after injection of [I-123]IACFT was significantly higher (p < 0.01) than with [C-11]CFT; similar to 6: 1 versus similar to 2.5: 1. After MPTP treatment this ratio decreased to 1.02:1 with IACFT and 1.23:1 with [C-11]CFT. Blood clearance of [I-123]IACFT was rapid with a terminal t(1/2) of similar to 30 min. HPLC of plasma samples demonstrated that the concentration of intact ligand decreases rapidly, approaching zero by 60 min. Low levels of accumulation were measured in extracranial tissues. Conclusion: These results demonstrate that [I-123]IACFT is an excellent SPECT ligand far dopamine transporter sites that combines the critical characteristics of: (a) high striatal to cerebellar ratios, (b) high selectivity for dopamine versus 5-HT transporter sites, (c) convenient preparation at high-specific activity and radiochemical purity and (d) a striatal localization rate that is well matched to the physical t(1/2) of I-123.
引用
收藏
页码:144 / 150
页数:7
相关论文
共 50 条
  • [21] GRAFTED EMBRYONIC DOPAMINE NEURONS RESTORE CYTOCHROME-OXIDASE ACTIVITY IN THE STRIATUM OF MPTP-TREATED MONKEYS
    COLLIER, TJ
    SLADEK, JR
    ELSWORTH, JD
    ROTH, RH
    TAYLOR, JR
    REDMOND, DE
    EXPERIMENTAL NEUROLOGY, 1995, 135 (02) : 162 - 162
  • [22] MULTIMODALITY AND COGNITIVE EVOKED-POTENTIALS IN MPTP-TREATED MONKEYS
    GHILARDI, MF
    ONOFRJ, M
    GLOVER, A
    MARX, M
    BODISWOLLNER, I
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 1987, 34 (3-4) : 178 - 179
  • [23] Striatal Dopaminergic Denervation and Spine Loss in MPTP-Treated Monkeys
    Villalba, Rosa M.
    Lee, Heyne
    Raju, Dinesh
    Smith, Yoland
    BASAL GANGLIA IX, 2009, 58 : 361 - 375
  • [24] Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys
    Villalba, Rosa M.
    Lee, Heyne
    Smith, Yoland
    EXPERIMENTAL NEUROLOGY, 2009, 215 (02) : 220 - 227
  • [25] Cortical Serotonergic and Catecholaminergic Denervation in MPTP-Treated Parkinsonian Monkeys
    Masilamoni, Gunasingh Jeyaraj
    Weinkle, Allison
    Papa, Stella M.
    Smith, Yoland
    CEREBRAL CORTEX, 2022, 32 (09) : 1804 - 1822
  • [26] Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys
    Juan Fernández-Ruiz
    Doris Doudet
    Thomas G. Aigner
    Psychopharmacology, 1999, 147 : 104 - 107
  • [27] Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys
    Fernández-Ruiz, J
    Doudet, D
    Aigner, TG
    PSYCHOPHARMACOLOGY, 1999, 147 (01) : 104 - 107
  • [28] Alpha synuclein expression in MPTP-treated 2 monkeys.
    Emborg, ME
    Chu, Y
    Giasson, B
    Lee, VM
    Domino, E
    Moirano, J
    Evans, M
    Kladis, T
    Collier, T
    Kordower, JH
    Trojanowski, J
    EXPERIMENTAL NEUROLOGY, 2003, 181 (01) : 90 - 90
  • [29] DISTRIBUTION OF STRIATAL DOPAMINE D-3 RECEPTORS IN THE NORMAL AND MPTP-TREATED COMMON MARMOSET
    HURLEY, MJ
    JOLKKONEN, J
    JENNER, P
    BRITISH JOURNAL OF PHARMACOLOGY, 1994, 112 : U146 - U146
  • [30] Binding potential evaluation of 123I-PE21, a new specific dopamine transporter ligand, by kinetic approach in healthy and MPTP-treated monkeys
    Caroline, C
    Chalon, S
    Aesch, B
    Bezard, E
    Benderbous, S
    Besnard, JC
    Guilloteau, D
    Baulieu, JL
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 1010 - 1010